支气管哮喘是一种常见的全球性气道慢性炎症性疾病,世界各地患病率为1%～13%,我国为1%～4%[1]。全球约1.6亿人患有哮喘[1],50%以上的成人及至少80%的儿童患者均由过敏因素诱发[2]。目前,过敏性哮喘(简称哮喘)仍然缺乏有效的治疗方法,而变应原特异性免疫治疗(specific im-munoth Bronchial asthma is a common global chronic inflammatory disease of the airways with prevalences ranging from 1% to 13% worldwide and 1% to 4% in our country [1]. Almost 160 million people worldwide have asthma [1], and more than 50% of adults and at least 80% of children are allergic to each other [2]. Currently, allergic asthma (asthma) still lacks an effective treatment, and allergen-specific immunotherapy (specific im-munoth